Table 2.

Pearson correlations between Pro-C2 levels in axial spondyloarthritis and psoriatic arthritis and clinical parameters

	axSpA				PsA
	Total (n = 110)	Treatment-naïve (n = 34)	Currently treated, total (n = 63)	Previously treated (n = 13)	Total (n = 101)	Treatment-naïve (n = 13)	Currently treated, total (n = 76)	Previously treated (n = 12)
Age	ns	ns	ns	ns	ns	r = −0.55	ns	ns
						p = −0.051
BMI	ns	ns	ns	ns	ns	r = 0.60	ns	ns
						p = 0.032
Disease duration	ns	ns	ns	r = 0.54	ns	r = 0.55	ns	ns
				p = 0.030		p = 0.052
ASDAS	ns	r = 0.45	ns	ns	ns	ns	ns	ns
		p = 0.008
HAQ	ns	ns	r = 0.47	ns	r = −0.34	ns	r = −0.35	ns
			p = 0.010		p = 0.004		p = 0.008
Sex	ns	ns	ns	ns	ns	ns	ns	ns
BASDAI	ns	ns	ns	ns	ns	ns	ns	ns
BASFI	ns	ns	r = −0.30	ns	ns	ns	ns	ns
			p = 0.008
SJC68	ns	ns	ns	ns	ns	ns	ns	r = −0.92
								p = 0.0001
TJC68	ns	ns	ns	ns	ns	ns	ns	r = −0.89
								p = 0.0003

Abbreviations: ASDAS Ankylosing Spondylitis Disease Activity Score, axSpA axial spondyloarthritis, BASDAI Bath Ankylosing Spondylitis Disease Activity Index, BASFI Bath Ankylosing Spondylitis Functional Index, BASMI Bath Ankylosing Spondylitis Metrology Index, BMI body mass index, HAQ Health Assessment Questionnaire, ns not significant, SJC68 68 swollen joint count, TJC68 68 tender joint count